DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20221987
Published: 2022-07-27

Role of Remdesivir therapy in COVID-19 patients: a systematic review and meta-analysis

Shabarini Srikumar, Aravind Muthiah, Shridharan Perumal

Abstract


The rapid global spread of corona virus disease has created an adversity for the scientific community in managing the disease with appropriate therapeutic measures. The use of remdesivir was initiated as an experimental drug and the later studies analyzing its efficacy showed mixed results. In this meta-analysis, we systematically review the efficacy and safety of remdesivir for the treatment and prevention of COVID-19. A systematic search of databases such as Pubmed, Lancet, Medline, Google Scholar, Cochrane, Embase was carried out through which 1451 articles were identified. 8 articles among it were finally taken for the meta-analysis after several stages of exclusion, to improve the quality and accuracy of the results, out of which the results of 4 studies were in favour of the efficacy of remdesivir, while other 4 studies were against the efficacy of remdesivir. The total sample size is 12,028. The result of our statistical analysis was that OR=0.965 (95% CI; 0.6633 to 1.47) for the effect of remdesivir on mortality reduction in COVID-19 patients. Remdesivir therapy for COVID-19 did not show reduced time to clinical recovery or improved mortality rate. Other outcomes of study like requirement of oxygen support, easier weaning off of mechanical ventilation were also not significantly improved with administration of remdesivir in critically ill COVID-19 patients.


Keywords


Antivirals, Pharmacotherapy, Remdesivir, SARS CoV 2

Full Text:

PDF

References


Srikumar S, Perumal S. A systematic review of immune pathogenesis of SARS-COV-2 infection. Int J Ad Med. 2021;8:978-83.

Statement on the second meeting of the International Health Regulations. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2005. Available at: https://www.who.int/ news-room/detail/30-01-2020-statemenonoutbreak-of-novel-coronavirus-(2019-ncov). Accessed on 24 May 2022.

Cohen PA, Hall LE, John JN, Rapoport AB. The early natural history of SARS-CoV-2 infection: clinical observations from an urban, ambulatory COVID-19 clinic. Mayo Clin Proc. 2020;95(6):1124-6.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and prevention. JAMA. 2020;323(13):1239-42.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.

de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110:16598-603.

de Wit E, Feldmann F, Cronin J. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117:6771-6.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383(19):1813-26.

Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS, Venkatachalam I. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection. 2021;49(3):401-10.

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795-807.

Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care [published online ahead of print, 2020 Jul 24]. Clin Infect Dis. 2020;ciaa1041.

Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(11):1048-57.

Gupta V, Ingawale S, Bhondve A, Khot W, Salagre S, Sonawale A, et al. Clinical Study of Use of Remdesivir and Tocilizumab in Severely Ill COVID-19 Patients. J Assoc Physicians India. 2021;69(7):14-9.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827-37.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-36.

Grein J, Myers RP, Brainard D. Compassionate Use of Remdesivir in Covid-19. Reply. N Engl J Med. 2020;382(25):e101.

Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899.

Sun D. Remdesivir for treatment of COVID-19: combination of pulmonary and iv administration may offer additional benefit. AAPS J. 2020;22(4):77.

World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. Published October 2018. Available at: https://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf. Accessed on 12 March 2022.